Evidence map›Paper›PMID 34279838›Full record

ReviewAdvances in experimental medicine and biology2021

Topical Oral and Intranasal Antiviral Agents for Coronavirus Disease 2019 (COVID-19).

Victor B Hsue, Kyohei Itamura, Arthur W Wu, Elisa A Illing, Kevin J Sokoloski, Bree A Weaver, Benjamin P Anthony, Nathan Hughes, Jonathan Y Ting, Thomas S Higgins

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Victor B HsueDepartment of Otolaryngology-Head and Neck Surgery, Cedars Sinai, Los Angeles, CA, USA.
Kyohei ItamuraDepartment of Otolaryngology-Head and Neck Surgery, Cedars Sinai, Los Angeles, CA, USA.
Arthur W WuDepartment of Otolaryngology-Head and Neck Surgery, Cedars Sinai, Los Angeles, CA, USA.
Elisa A IllingDepartment of Otolaryngology-Head and Neck Surgery, Indiana University, Indianapolis, IN, USA.
Kevin J SokoloskiDepartment of Microbiology and Immunology, University of Louisville, Louisville, KY, USA.
Bree A WeaverDivision of Infectious Diseases, Departments of Internal Medicine and Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.
Benjamin P AnthonyDepartment of Otolaryngology-Head and Neck Surgery, Indiana University, Indianapolis, IN, USA.
Nathan HughesPharmacy Operations, Kindred Healthcare Support Center, Louisville, KY, USA.
Jonathan Y TingDepartment of Otolaryngology-Head and Neck Surgery, Indiana University, Indianapolis, IN, USA.
Thomas S HigginsDepartment of Otolaryngology-Head and Neck Surgery and Communicative Disorders, University of Louisville, Louisville, KY, USA. thomas.higgins@louisville.edu.
Cedars-Sinai Medical Center · USIndiana University – Purdue University Indianapolis · USUniversity of Louisville · USIndiana University School of MedicineUniversity of Kentucky HealthCare · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the largest viral loads in both symptomatic and asymptomatic patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) present in the oral and nasal cavities, agents that act on these two areas have the potential for large therapeutic and prophylactic benefit. A literature review was conducted to elucidate the possible agents useful in treatment of SARS-CoV-2. These agents were evaluated for their current applications, adverse reactions, their current state of study, and any future considerations in their management of coronavirus disease 2019 (COVID-2019). Our review has found that, while there are many promising agents with proven efficacy in their in-vitro efficacy against SARS-CoV-2, more clinical trials and in-vivo studies, as well as safety trials, must be conducted before these agents can be effectively implemented.

Indexed as

COVID-19Antiviral AgentsHumansSARS-CoV-2Viral LoadAntiviral AgentsAntiviral agentsCoronavirusCOVID-19NasalNasopharynxOralPublic healthSevere acute respiratory syndrome coronavirus 2Topical

Identifiers

PMID34279838
OpenAlexW3185218366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.